The head of a biosimilar company says CMS is allowing interchangeability within its Part D formulary by not considering the reference and biosimilar products as different drugs to satisfy the two distinct drugs requirement for each categories and classes. However, a health policy analyst said this interpretation is opposite of what CMS says, and that the agency is taking a particularly conservative approach that does not encroach on FDA and is supportive of FDA determinations. CMS released three memos in...